RICHMOND, Va., Nov. 1, 2021 /PRNewswire/ -- Indivior PLC
(LON: INDV) announced today the presentation of data at the
National Commission on Correctional Healthcare Conference (NCCHC)
from a mixed methods study examining opioid use disorder (OUD)
treatment barriers in the criminal justice system.1 The
study entitled, Factors Impacting Medication for Opioid Use
Disorder (MOUD) Treatment Decisions in Criminal Justice-involved
Populations, demonstrated factors influencing treatment
approaches including preferred treatment options, barriers to
treatment, and patient concerns.1 The National
Correctional Healthcare Conference takes place from October 30 to November 3, 2021.
The mixed methods study included a systematic review of
peer-reviewed literature published between 2016-2021 and
semi-structured interviews with eight addiction medicine
specialists, primary care physicians, and clinical and
administrative team members working in and with Tower Health, an
integrated health system in Pennsylvania. Additionally,
sample data from electronic health records (EHR) of 195 patients
treated with MOUD was analyzed to predict patient-related outcomes
such as number of emergency department (ED) visits and clinic
no-shows compared with criminal justice involved individuals and
non-criminal justice involved individuals. 1
"It is estimated that nearly 20 percent of individuals sentenced
to state prison report regular use of opioids,"2 said
Christian Heidbreder, Chief
Scientific Officer, Indivior. "Stigma and lack of resources has
resulted in unequal access to treatment for people who are
incarcerated. We must continue to advocate for expanded access to
medication for opioid use disorder treatment in correctional
settings and focus our efforts on helping people access the
treatments they need to achieve and maintain recovery."
The qualitative analysis included interviews with participants
to gauge their opinions regarding MOUD treatment for criminal
justice-involved populations. 1 The interviews revealed
that all eight addiction medicine team members favored the use of
the monthly injectable version of buprenorphine for most people
with OUD. Study participants also indicated patients expressed
anxiety about trying a new medication and having concerns of
withdrawal as a component of treatment decisions, among other
factors.1
The statistical analysis from sample electronic health records
EHR data revealed that when patients were offered MOUD treatment,
likelihood of ED visits or clinic no-shows were the same for
criminal justice-involved patients and non-criminal
justice-involved patients.1
Additionally, the data presented also showed that individuals
with criminal justice-involvement face greater limitations in
access to treatment than patients with no involvement in the
criminal justice system.1
About the study methods
The mixed methods study included a systematic literature review,
in-depth interviews with addiction medicine specialists working in
and with Tower Health, an integrated health system in Pennsylvania, and analysis of a sample from
the Tower Health Electronic Health Record. Logistic regression
models were used to estimate associations of various factors with
emergency department visits and clinic no-show rates among patients
being treated with MOUD. The study explored factors influencing
treatment approaches, including the use of the monthly injectable
version of buprenorphine, for individuals with OUD, with a
particular focus on patients with CJI.1
Study limitations included the involvement of one health system
and a small number of patient health records. Additionally,
criminal justice-involvement was identified through review of
electronic health records (EHR) documentation which relies on
providers asking about criminal justice-involvement and patient
self-reports.
About Indivior
Indivior is a global pharmaceutical company working to help
change patients' lives by developing medicines to treat addiction
and serious mental illnesses. Our vision is that all patients
around the world will have access to evidence-based treatment for
the chronic conditions and co-occurring disorders of addiction.
Indivior is dedicated to transforming addiction from a global human
crisis to a recognized and treated chronic disease. Building on its
global portfolio of opioid dependence treatments, Indivior has a
pipeline of product candidates designed to both expand on its
heritage in this category and potentially address other chronic
conditions and cooccurring disorders of addiction, including
alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 800
individuals globally and its portfolio of products is available in
over 40 countries worldwide. Visit www.indivior.com to learn more.
Connect with Indivior on LinkedIn by visiting
www.linkedin.com/company/indivior.
References:
- Bailey K, Gusmano M, Millen W et al. (2021) Factors impacting
MOUD treatment decisions in criminal justice-involved
populations.
- SAMHSA. Medication Assisted Treatment (MAT) in the Criminal
Justice System. Brief Guidance to the States. Published
March 2019.
https://store.samhsa.gov/sites/default/files/d7/priv/pep19-matbriefcjs_0.pdf
SUBLOCADE (buprenorphine extended-release) injection, for
subcutaneous use (CIII)
INDICATION AND HIGHLIGHTED SAFETY INFORMATION
INDICATION
SUBLOCADE is indicated for the treatment of moderate to severe
opioid use disorder in patients who have initiated treatment with a
transmucosal buprenorphine-containing product, followed by dose
adjustment for a minimum of 7 days.
SUBLOCADE should be used as part of a complete treatment plan
that includes counseling and psychosocial support.
HIGHLIGHTED SAFETY INFORMATION
|
WARNING: RISK OF
SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE
RISK EVALUATION AND MITIGATION STRATEGY
|
|
|
•
|
Serious harm or
death could result if administered intravenously.
SUBLOCADE forms a solid mass upon contact with body fluids and
may cause occlusion, local tissue damage, and thrombo-embolic
events, including life threatening pulmonary emboli, if
administered intravenously.
|
|
|
|
•
|
Because of the
risk of serious harm or death that could result from
intravenous self-administration, SUBLOCADE is only available
through a restricted program called the SUBLOCADE REMS Program.
Healthcare settings and pharmacies that order and dispense
SUBLOCADE must be certified in this program and comply with the
REMS requirements.
|
|
|
Prescription use of this product is limited under the Drug
Addiction Treatment Act.
CONTRAINDICATIONS
SUBLOCADE should not be administered to patients who have been
shown to be hypersensitive to buprenorphine or any component of the
ATRIGEL® delivery system
WARNINGS AND PRECAUTIONS
Addiction, Abuse, and Misuse: SUBLOCADE contains
buprenorphine, a Schedule III controlled substance that can be
abused in a manner similar to other opioids. Monitor patients for
conditions indicative of diversion or progression of opioid
dependence and addictive behaviors.
Respiratory Depression: Life threatening respiratory
depression and death have occurred in association with
buprenorphine. Warn patients of the potential danger of
self-administration of benzodiazepines or other CNS depressants
while under treatment with SUBLOCADE.
Opioids can cause sleep-related breathing disorders e.g.,
central sleep apnea (CSA), sleep-related hypoxemia. Opioid use
increases the risk of CSA in a dose-dependent fashion. Consider
decreasing the opioid using best practices for opioid taper if CSA
occurs.
Strongly consider prescribing naloxone at SUBLOCADE initiation
or renewal because patients being treated for opioid use disorder
have the potential for relapse, putting them at risk for opioid
overdose. Educate patients and caregivers on how to recognize
respiratory depression and how to treat with naloxone if
prescribed.
Risk of Serious Injection Site Reactions: The most common
injection site reactions are pain, erythema and pruritis with some
involving abscess, ulceration, and necrosis. The likelihood of
serious injection site reactions may increase with inadvertent
intramuscular or intradermal administration.
Neonatal Opioid Withdrawal Syndrome: Neonatal opioid
withdrawal syndrome is an expected and treatable outcome of
prolonged use of opioids during pregnancy.
Adrenal Insufficiency: If diagnosed, treat with physiologic
replacement of corticosteroids, and wean patient off the
opioid.
Risk of Opioid Withdrawal With Abrupt Discontinuation: If
treatment with SUBLOCADE is discontinued, monitor patients for
several months for withdrawal and treat appropriately.
Risk of Hepatitis, Hepatic Events: Monitor liver function
tests prior to and during treatment.
Risk of Withdrawal in Patients Dependent on Full Agonist
Opioids: Verify that patient is clinically stable on
transmucosal buprenorphine before injecting SUBLOCADE.
Treatment of Emergent Acute Pain: Treat pain with a
non-opioid analgesic whenever possible. If opioid therapy is
required, monitor patients closely because higher doses may be
required for analgesic effect.
ADVERSE REACTIONS
Adverse reactions commonly associated with SUBLOCADE (in ≥5% of
subjects) were constipation, headache, nausea, injection site
pruritus, vomiting, increased hepatic enzymes, fatigue, and
injection site pain.
For more information about SUBLOCADE, the full Prescribing
Information including BOXED WARNING, and Medication Guide, visit
www.sublocade.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/indivior-presents-study-at-the-2021-national-commission-on-correctional-healthcare-conference-on-factors-impacting-medications-for-opioid-use-disorder-treatment-approaches-in-criminal-justice-involved-populations-301413363.html
SOURCE Indivior